Topical kanamycin: an effective therapeutic option in aerobic vaginitis.
Eighty-one patients with clinical diagnosis of aerobic vaginitis (AV) were included in the study. The patients were randomized for treatment, 45 with kanamycin (100 mg vaginal ovules for 6 days, consecutively) and 36 with meclocycline (35 mg vaginal ovules for 6 days, consecutively). The patients were examined before starting the study, 1-2 days after treatment and 30 days after the end of the study. At the first follow-up the patients showed different levels of symptom reduction. Reduction in the presence of leukocytes, vaginal mucosa burning and itching were statistically significant in the group treated with kanamycin with respect to the group treated with meclocycline. Moreover, there was also reduced isolation of Enterobacteriaeae (97%) in the group treated with kanamycin versus those treated with meclocycline (76%). At the second follow-up, vaginal homeostasis (normalization of pH and presence of lactobacilli) was more evident in the kanamycin-treated group. In conclusion, our data suggest that the topical use of kanamycin could be considered a specific antibiotic for the therapy of this new pathology.
Tempera
G
G
Department of Microbiological and Gynecological Sciences, University of Catania, Via Androne 81, 95124 Catania, Italy. tempera@unict.it
Abbadessa
G
G
Bonfiglio
G
G
Cammarata
E
E
Cianci
A
A
Corsello
S
S
Raimondi
A
A
Ettore
G
G
Nicolosi
D
D
Furneri
P M
PM
D000287:Administration, Topical; D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001420:Bacteria, Aerobic; D005260:Female; D006801:Humans; D007612:Kanamycin / Q000494:pharmacology / Q000627:therapeutic use*; D007778:Lactobacillus / Q000187:drug effects; D010118:Oxytetracycline / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D014627:Vaginitis / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; C100122:meclocycline; D007612:Kanamycin; D010118:Oxytetracycline